The safety and feasibility of multiple intrathecal injections of allogenic NK cells in pediatrics with refractory/recurrent brain tumors DOI Creative Commons
Hamid Mahdizadeh,

Amirhossein Izadpanah,

Yasaman Nouri

et al.

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: May 27, 2025

Pediatric glioma is a rare condition that can lead to significant mortality and morbidity due its high recurrence rate. This study phase I nonrandomized clinical trial was conducted assess the safety, feasibility, potential efficacy of intrathecal (IT) injection multiple doses allogenic NK cells in pediatric patients with refractory/recurrent gliomas. Allogeneic were isolated from random healthy unrelated donors via positive selection CD56 + cells. Nine selected according inclusion criteria received weekly up 10 5 × 107 cells/injection. Adverse events grading done based on Common Terminology Criteria for Events (CTCAE) Check lists. The size tumor, degree spinal spreading duration relapse during 18 month followup considered components efficacy. Additionally, six who conventional treatment retrospectively. Multiple injections allogeneic gliomas safe, without any serious adverse (SAEs). most prevalent AEs headache [29% (17% grade 1 13% 2)], fever chills [21% 4% vomiting [13% 2], back pain [12% (4% 8% 2)]. months follow-up, among five intervention group still alive (August 7, 2024), three exhibited stable disease (SD), one had progressive (PD), experienced partial response (PR) reduction tumor size. Among four deceased patients, two died progression, infections. In retrospective control group, out developed PD leptomeningeal spread (LMS), whom died, patient showed radiological evidence complete (CR). Cerebrospinal fluid (CSF) analysis revealed increases percentages T reductions levels IFN-γ TNF-α. are safe feasible Although we reported episodes an increase overall survival, further studies extended follow-up periods appropriate groups necessary cell therapy these patients. registered Iranian Registry Clinical Trials (IRCT20170122032121N6), Date 2021-11-19.

Language: Английский

NK cell-based tumor immunotherapy DOI Creative Commons
Hao Zhang, Yang Li, Tingting Wang

et al.

Bioactive Materials, Journal Year: 2023, Volume and Issue: 31, P. 63 - 86

Published: Aug. 9, 2023

Natural killer (NK) cells display a unique inherent ability to identify and eliminate virus-infected tumor cells. They are particularly powerful for elimination of hematological cancers, have attracted considerable interests therapy solid tumors. However, the treatment tumors with NK less effective, which can be attributed very complicated immunosuppressive microenvironment that may lead inactivation, insufficient expansion, short life, poor infiltration Fortunately, development advanced nanotechnology has provided potential solutions these issues, could improve immunotherapy efficacy In this review, we summarize activation inhibition mechanisms in tumors, recent advances cell-based boosted by diverse nanomaterials. We also propose challenges opportunities clinical application immunotherapy.

Language: Английский

Citations

48
Antigen Self-Presented Personalized Nanovaccines Boost the Immunotherapy of Highly Invasive and Metastatic Tumors DOI
Tingting Wang,

Mengxiao Han,

Yaobao Han

et al.

ACS Nano, Journal Year: 2024, Volume and Issue: 18(8), P. 6333 - 6347

Published: Feb. 13, 2024

Dendritic cell (DC)-based vaccines have shown promise in adoptive therapy for enhancing the antigen-specific response of antitumor immunity. However, their clinical efficacy is limited by less-presented tumor-associated antigens (TAAs) through MHC I and low lymph node homing efficiency. Herein, to address these issues, we rationally design fabricate DC-based nanovaccines coating Cu2–xSe nanoparticles (CS NPs) with membrane matured DCs (named as DCNV(CSD) nanovaccines). We reveal important roles CS NPs from three aspects: (1) inducing immunogenic death tumor cells expose abundant TAAs; (2) promoting escape TAAs lysosomes during antigen presenting process I; (3) sustainably releasing traces copper ions promote proliferation T cells. Our are characterized high expressions I, CD80, CD86, CCR7, ICAM-1 proteins, which not only endow them abundantly processed specific TAAs, but also a strong capability nodes. The our small better than that DCs. More importantly, they can elicit potent antispecific CD8+ immunotherapy, tested treatment highly invasive glioblastoma metastatic melanoma. Additionally, generate memory (TEM) spleen mice effectively prevent recurrence treated tumors. This work demonstrates universal approach high-performance immunotherapy using versatile NPs.

Language: Английский

Citations

18
Brain-Targeting Drug Delivery Systems: The State Of The Art In Treatment Of Glioblastoma DOI Creative Commons

Bo Sun,

Rong Li, Ning Ji

et al.

Materials Today Bio, Journal Year: 2025, Volume and Issue: 30, P. 101443 - 101443

Published: Jan. 5, 2025

Glioblastoma (GBM) is the most prevalent primary malignant brain tumor, characterized by a high mortality rate and poor prognosis. The blood-brain barrier (BBB) blood-tumor (BTB) present significant obstacles to efficacy of tumor-targeted pharmacotherapy, thereby impeding therapeutic potential numerous candidate drugs. Targeting delivery adequate doses drug across BBB treat GBM has become prominent research area in recent years. This emphasis driven exploration evaluation diverse technologies for with some already undergoing clinical trials. review provides thorough overview advancements challenges targeted treatment. It specifically emphasizes systemic administration strategies assess their limitations Furthermore, this highlights promising future directions development intelligent systems aimed at overcoming current enhancing against GBM. These not only support foundational on but also offer methodological approaches applications.

Language: Английский

Citations

4
Copper-Based Biomaterials for Anti-Tumor Therapy: Recent Advances and Perspectives DOI
Shufang Zhang, Shuping Peng

Acta Biomaterialia, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

2
Reversing T Cell Dysfunction to Boost Glioblastoma Immunotherapy by Paroxetine‐Mediated GRK2 Inhibition and Blockade of Multiple Checkpoints through Biomimetic Nanoparticles DOI Creative Commons
Tingting Wang, Hao Zhang,

Yaobao Han

et al.

Advanced Science, Journal Year: 2023, Volume and Issue: 10(9)

Published: Jan. 25, 2023

Abstract T cell dysfunction‐induced tumor immune escape is particularly severe in glioblastoma (GBM), and significantly affects the efficacy of immunotherapy. It crucial to innovatively reverse dysfunction for improving GBM Herein, remarkably reversed immunotherapy boosted by repurposing U. S. Food Drug Administration‐approved antidepressant paroxetine (PX) with biomimetic nanoparticles (CS‐J@CM/6 NPs). The PX successfully applied abrogate sequestration bone marrow GBM‐bearing mice increase their infiltration tumor. NPs are composed ultrasmall Cu 2− x Se NPs, JQ1, membrane modified CD6, efficiently delivered into through specific interactions between CD6 activated leukocyte adhesion molecule. They ameliorate double roles loaded which simultaneously decreases expression PD‐1 TIM‐3 on cells, PD‐L1 cells. NP also induces immunogenic death cells activate response. synergistic CS‐J@CM/6 notably enhance survival mice. This work provides new insights “old drugs” advanced NPs.

Language: Английский

Citations

30
Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression DOI Creative Commons

Yunna Chen,

Qianqian Zhou,

Zongfang Jia

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2024, Volume and Issue: 14(9), P. 3834 - 3854

Published: June 3, 2024

Immunotherapy is an important cancer treatment method that offers hope for curing patients. While immunotherapy has achieved initial success, a major obstacle to its widespread adoption the inability benefit majority of The success or failure closely linked tumor's immune microenvironment. Recently, there been significant attention on strategies regulate tumor microenvironment in order stimulate anti-tumor responses immunotherapy. distinctive physical properties and design flexibility nanomedicines have extensively utilized target cells (including tumor-associated macrophages (TAMs), T cells, myeloid-derived suppressor (MDSCs), fibroblasts (TAFs)), offering promising advancements In this article, we reviewed aimed at targeting various focus models are based nanomedicines, with goal inducing enhancing improve It worth noting combining other treatments, such as chemotherapy, radiotherapy, photodynamic therapy, can maximize therapeutic effects. Finally, identified challenges nanotechnology-mediated needs overcome more effective nanosystems.

Language: Английский

Citations

17
Recent Advances in Biomimetic Strategies for the Immunotherapy of Glioblastoma DOI

Haoyu You,

Shuo Geng,

Shangkuo Li

et al.

Biomaterials, Journal Year: 2024, Volume and Issue: 311, P. 122694 - 122694

Published: June 28, 2024

Language: Английский

Citations

10
Nano-Based Strategies Aiming at Tumor Microenvironment for Improved Cancer Therapy DOI
Tianhui Liu,

Changshun Lu,

Xue Jiang

et al.

Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 17, 2025

Malignant tumors pose a considerable threat to human life and health. Traditional treatments, such as radiotherapy chemotherapy, often lack specificity, leading collateral damage normal tissues. Tumor microenvironment (TME) is characterized by hypoxia, acidity, redox imbalances, elevated ATP levels factors that collectively promote tumor growth metastasis. This review provides comprehensive overview of the nanoparticles developed in recent years for TME-responsive strategies or TME-modulating methods therapy. The focus on designing synthesizing can interact with achieve precisely controlled drug release. These activate release under specific conditions within environment, thereby enhancing efficacy drugs while reducing toxicity cells. Moreover, simply eliminating cells does not fundamentally solve problem. Only comprehensively regulating TME make it unsuitable cell survival proliferation we more thorough therapeutic effects reduce risk recurrence. regulation aim suppress metastasis modulating various components TME. only improve treatment outcomes but also have potential lay foundation future personalized cancer therapies.

Language: Английский

Citations

1
Versatile Copper-Chalcogenide-Based Nanoparticles for the Treatment of Brain Diseases DOI Creative Commons
Shuyang Xie,

Hualong Liu,

Ke Yang

et al.

Nano Biomedicine and Engineering, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

1
Ameliorating Mitochondrial Dysfunction for the Therapy of Parkinson's Disease DOI
Qing Yin Zheng, Hanghang Liu, Yifan Gao

et al.

Small, Journal Year: 2024, Volume and Issue: 20(29)

Published: Feb. 22, 2024

Parkinson's disease (PD) is currently the second most incurable central neurodegenerative resulting from various pathogenesis. As "energy factory" of cells, mitochondria play an extremely important role in supporting neuronal signal transmission and other physiological activities. Mitochondrial dysfunction can cause accelerate occurrence progression PD. How to effectively prevent suppress mitochondrial disorders a key strategy for treatment PD root. Therefore, emerging mitochondria-targeted therapy has attracted considerable interest. Herein, relationship between PD, causes results dysfunction, major strategies ameliorating treat are systematically reviewed. The study also prospects main challenges

Language: Английский

Citations

8